Lung transplantation was associated with significantly longer early survival in selected patients with stage IV lung-limited non-small-cell lung cancer (NSCLC).
This prospective, single-center registry study included 98 adults with refractory, lung-limited non-small cell lung cancer (NSCLC) at stage IV. Of these, 17 underwent a lung transplant, while 81 met the eligibility criteria for transplantation but were unable to undergo the procedure due to logistical, financial or geographic barriers and received medical management alone.
All transplant recipients had respiratory failure, compared with 68% of medically managed patients. Those who receive a transplant also have a significantly worse functional status at baseline.
The estimated 1-year overall survival rate was 100% among transplant recipients compared with 40.8% among patients receiving medical therapy alone, an absolute difference of 59.2 percentage points. There were no deaths among transplant recipients during the initial comparative follow-up period, compared with 52 deaths among 81 medically managed patients.
Careful selection is essential for the lung transplantation approach
Eligible patients had progressive cancer despite recommended systemic therapies and disease confirmed to be limited to the lungs by comprehensive staging. Most recipients have undergone an organ transplant Bilateral lung transplant Using a surgical approach designed to reduce tumor spread.
All 17 transplant recipients had adenocarcinoma. Molecular profiling identified EGFR variations in three patients, KRAS variations in two, and BRAF V600E in one patient. All but two had previously received immune checkpoint inhibitors.
Early postoperative outcomes were broadly similar to those seen among 306 patients who underwent lung transplantation for end-stage lung disease without cancer. Estimated 1-year survival after transplantation was 100% in patients with NSCLC and 88.1% in cancer-free recipients.
Longer follow-up is needed to determine the clinical role
The fight against cancer has not been universal. Four of the 17 transplant recipients developed recurrence or overt progression of NSCLC. In extended follow-up until January 31, 2026, two transplant recipients died.
Thus, the results do not indicate that lung transplantation restores normal life expectancy or represents a stable treatment for stage IV NSCLC. Instead, they suggest a potential survival benefit in a narrowly selected population with limited lung disease, debilitating systemic treatment options, and respiratory failure.
The authors note that the small sample size, single-center setting, nonrandomized design, and specialized experience in organ transplantation limit generalizability. Long-term follow-up, including assessment of late recurrence, complications and quality of life, will be needed to determine whether lung transplantation can play a broader role in selected patients with advanced lung cancer.
reference
Bharat A et al. Lung transplantation for patients with refractory stage IV non-small cell lung cancer. Gamma. 2026;336(6):484-495.
Featured Image: Stunning Studio on Adobe Stock.
